Multiple sclerosis (MS) has no cure, but treatment has improved dramatically over the past two decades. The goal is threefold: slow the disease itself with long-term medications, manage relapses when they happen, and treat the day-to-day symptoms that affect quality of life. Most people with MS use some combination of all three approaches, tailored to their specific type of MS and how active it is.
Disease-Modifying Therapies
Disease-modifying therapies, or DMTs, are the backbone of MS treatment. These medications don’t fix existing damage, but they reduce how often relapses occur and slow the accumulation of disability over time. Current DMTs reduce annual relapse rates by roughly 29% to 68% compared to placebo, depending on the drug. They come in three main forms: pills, injections, and infusions.
The oldest options are injectable drugs, including interferon beta and glatiramer acetate. These work by shifting the immune system away from the inflammatory response that attacks the protective coating around nerves. They’ve been used since the 1990s and have well-established safety profiles, though they require regular self-injections.
Oral DMTs became available more recently and are often preferred for convenience. Fingolimod works by trapping certain immune cells in the lymph nodes so they can’t reach the brain and spinal cord. Dimethyl fumarate activates a protective antioxidant pathway. Teriflunomide blocks an enzyme that rapidly dividing immune cells need to reproduce. Each has a different side effect profile, so the choice often depends on your health history and tolerance.
Infusion therapies tend to be the most potent. Natalizumab blocks immune cells from crossing into the central nervous system. Alemtuzumab depletes a broad population of immune cells, essentially resetting part of the immune system. These are typically reserved for more aggressive disease or for people who haven’t responded well to other treatments, because stronger suppression of the immune system carries higher risks of infection.
Options for Progressive MS
Most DMTs were developed for relapsing-remitting MS, the most common form. Progressive MS, where disability worsens steadily rather than in distinct attacks, has historically had far fewer options. That picture is slowly changing.
Ocrelizumab is currently the only FDA-approved treatment for primary progressive MS. It targets a specific type of immune cell called B cells and has been shown to slow the rate of disability progression. For secondary progressive MS, where the disease transitions from a relapsing pattern to a more steady decline, siponimod and cladribine are both approved. Siponimod is a daily oral pill that reduces relapse rates and helps slow progression. Some DMTs originally approved for relapsing MS can also benefit people with secondary progressive disease, particularly if relapses are still occurring.
Treating Relapses
A relapse, sometimes called an exacerbation or flare, is a new or worsening neurological symptom that lasts at least 24 hours. Not every relapse requires treatment, but when symptoms are significant, the standard approach is a short course of high-dose corticosteroids, typically given intravenously over three to five consecutive days. This reduces inflammation quickly and can shorten the duration of a relapse, though it doesn’t change the long-term course of the disease.
For severe relapses that don’t respond to corticosteroids, or for people who can’t tolerate them, plasmapheresis is an alternative. This procedure filters the blood to remove the antibodies attacking the nervous system. It’s not used routinely, but it can make a meaningful difference in serious flares.
Managing Everyday Symptoms
MS produces a wide range of symptoms beyond relapses, and managing these is a major part of treatment. The specifics depend on which nerves are affected, but a few issues are especially common.
Fatigue is the most frequently reported symptom. Treatment plans typically combine medication with energy conservation strategies, rehabilitation therapy, and dietary changes. Learning to pace activities and prioritize rest can be as effective as any pill.
At least 80% of people with MS experience bladder dysfunction at some point. Options range from lifestyle adjustments and pelvic floor physical therapy to medications that calm an overactive bladder. Nerve stimulation procedures are another option when medications aren’t enough.
Spasticity, the stiffness and involuntary muscle tightness that can make movement difficult, is commonly managed with a combination of physical therapy and muscle relaxants like baclofen. Targeted injections can help when spasticity is concentrated in specific muscle groups. Occupational therapy helps people adapt their daily routines to work around these limitations.
Rehabilitation and Multidisciplinary Care
Rehabilitation isn’t a one-time event for MS. It’s an ongoing part of treatment that can include physical therapy, occupational therapy, speech therapy, and other disciplines depending on your needs. Structured rehabilitation programs, whether inpatient or outpatient, have strong evidence behind them. They improve overall disability levels, mobility, self-care ability, and bladder control. Programs that combine multiple therapy types tend to produce the best results.
A typical outpatient program might involve an hour of physical therapy five days a week alongside shorter occupational therapy sessions. Inpatient programs are more intensive, sometimes including two physical therapy sessions per day. The right intensity depends on your current level of function and what you’re trying to achieve. Even short, high-intensity programs have been shown to improve mobility and daily functioning, at least in the short term.
Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation (aHSCT) is a more aggressive option that essentially reboots the immune system. Your own stem cells are collected, your existing immune system is wiped out with chemotherapy, and then the stem cells are reinfused to rebuild it from scratch.
The results vary significantly by MS type. For people with relapsing MS, 73% remained free from disability progression five years after the procedure. For secondary progressive MS, that number dropped to 33%. Overall, about half of all transplanted patients were progression-free at five years. Because of the risks involved with intensive chemotherapy, this treatment is generally considered for people with highly active relapsing disease who haven’t responded to conventional DMTs.
How Treatment Is Monitored
Once you’re on a DMT, your neurologist will track whether the treatment is working using a framework called NEDA-3, which stands for “no evidence of disease activity.” It has three components: no clinical relapses, no new or enlarging lesions on MRI, and no worsening of disability. Meeting all three criteria means the disease is well controlled.
MRI scans are typically performed about once a year to check for new brain or spinal cord lesions, even if you feel fine. If breakthrough activity appears on imaging or you experience new relapses, your neurologist may recommend switching to a different or stronger DMT. The wide range of available medications means there are usually several alternatives to try if the first choice isn’t providing enough control.